INTRODUCTION
Influenza remains a significant public health problem, causing seasonal annual epidemics, occasional widespread pandemics, and sporadic high pathogenicity outbreaks in domestic animals. In humans, two influenza A virus (IAV) strains (H1N1 and H3N2) along with one influenza B virus (IBV), from either the Victoria and Yamagata lineage, co-circulate annually (1) . Vaccination with an inactivated influenza virus is currently the most effective way of inducing strain-specific neutralizing antibodies directed against surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). In the absence of antibodymediated immunity, preexisting memory B cells (2, 3) and broadly cross-reactive memory T cells (4) (5) (6) can be recalled and protect against influenza. Because of the antigenic drift (accumulation of mutations in antigenic regions) of IAV and IBV, and antigenic shifts (generation of antigenically novel strains through recombination) of IAV, broadly cross-reactive memory B cell and T cell populations might be central for controlling antigenically distinct influenza strains. Thus, effective influenza vaccines need to establish long-lasting memory B cells and T cells, readily recalled during infection with novel influenza viruses.
After antigen reexposure, memory B cells develop into short-lived effectors [plasmablasts and plasma cells, jointly named as antibodysecreting cells (ASCs)] and rapidly provide antibodies. In addition, memory B cells reenter germinal centers, resulting in generation of affinity-matured long-lived plasma cells (LLPCs) and memory B cells (7, 8) . This process depends on costimulation and cytokine production by T follicular helper (T FH ) cells (9, 10) . After inactivated influenza vaccine (IIV), a transient population of ASCs, predominantly derived from memory B cells outside the germinal centers, emerges in peripheral blood on day 7 (d7) after vaccination and correlates with antibody titers (2, 11) . Concomitantly, a population of circulating T FH (cT FH ; CD4 + CXCR5 + ) cells (12) also emerges in peripheral blood on d7 after vaccination (13) . These cT FH cells exhibit a type 1 phenotype (CXCR3 + CCR6 − ), express activation markers (ICOS and PD-1), provide help to memory (but not naïve) B cells for development into ASCs, and correlate with ASCs and antibody responses (13) . However, the role of human cT FH cells in establishing B cell memory is not entirely understood. Recent studies described new subsets of antigen-specific B cells, based on the expression of CD21 and CD71, emerging with variable dynamics after immunization (14, 15) . In addition, influenza exposure history and preexisting antibodies can shape the antibody response to IIV (16) (17) (18) , although mechanisms are ill defined. Important questions remain with regard to the generation and maintenance of immune memory B cells and T cells after IIV.
Here, we dissected cellular events that precede the serological response to IIV as well as the tissue distribution of influenza-specific memory B cells across human tissues. These findings have fundamental implications for the rational design of vaccines that induce protective and long-lasting immunity against influenza viruses.
RESULTS

Influenza vaccination induces activation of cT FH cells and expansion of CXCR3 +
CXCR5
− ASCs To dissect the cellular events preceding generation of protective immunity to IIV, blood samples were obtained from healthy adults at baseline and on d7, d14, and d28 after intramuscular immunization. Our study involved 35 vaccinees aged 22 to 55 years old, over 3 years, with a total sample size of 42 (table S1). The vaccination history of the donors was unknown. A/California/7/2009 remained constant throughout 3 years of vaccination, whereas A/H3N2 and IBV components were updated annually to reflect antigenically drifted A/H3N2 strains and circulating Yamagata or Victoria IBV viruses (Fig. 1A) . S2D ). These data show that vaccination with IIV specifically activates cT FH 1 cells.
As previously reported (2, 11) , ASCs transiently appeared in blood peaking on d7 after vaccination (P < 0.0001 compared to baseline) and then declining at d14 and d28 (Fig. 1, F and G) . We found a transient increase in expression of CXCR3 on ASCs on d7 (P < 0.001) (Fig. 1, H and I) , not observed on non-ASC (non-CD38 hi CD27 + ) B cells (P < 0.0001) (Fig. 1J ). In addition, although non-ASC B cells expressed CXCR5, circulating ASCs lacked CXCR5 expression (P < 0.0001) (Fig. 1K) . Thus, circulating ASCs present in blood on d7 after vaccination display distinct expression patterns of chemokine receptors, CXCR3 and CXCR5, important for trafficking of B cells. Vaccination also increased serum antibody titers (d28 compared to baseline) against A/H1N1, A/H3N2, and IBV components (Fig. 1L) , based on the HA inhibition assay (HAI). This assay measures serum antibodies that block the receptor binding on the HA head (but not binding to HA stem), irrespective of isotype. These data show that IIV induces transient and concurrent changes in circulatory B cell and T FH compartments.
Recombinant HA probes detect influenza-specific B cells
To determine the quantity, phenotype, and isotype of B cells elicited by IIV, we identified influenza-specific B cells with recently developed recombinant HA (rHA) probes (19) (20) (21) , consisting of four biotinylated trimeric rHA molecules conjugated to streptavidinfluorochrome com plexes. To prevent nonspecific binding to sialic acids on the cell surface, rHA probes contained mutations Y98F for IAV and T190G for IBV (21) . We used rHA probes against three vaccine components: A/California/07/09-H1N1 (A/Cal09-H1), A/ Switzerland/9715293/2013-H3N2 (A/Swi-H3), and B/Phuket/3073/2013 (BHA; Yamagata lineage) ( Fig. 2A) . Using peripheral blood mononuclear cells (PBMCs) from healthy adults, influenza probe-specific B cells were identified within mature class-switched CD19 Fig. 2A and fig. S3 ).
We validated the specificity of rHA probes for detection of influenzaspecific B cells using different experimental approaches (figs. S4 and S5). Dual rHA probe staining (two rHA probes of the same specificity conjugated to different fluorochromes) (22) showed that most of the class-switched IgD − B cells were double-positive across allophycocyanin (APC)-and phycoerythrin (PE)-conjugated probes (97 and 90% for H1; 92 and 50% for H3; 91 and 86% for B; fig. S4 , A and B), reflecting a high level of probe specificity. Because of its higher sensitivity, our subsequent data were generated using the H3-APC probe. However, double-positive rHA staining within unswitched IgD S5B ). Because clonality is a function of sequencing depth, some of the singletons would also likely be HA-specific. In addition, our data show that the rHA-specific singletons use the same heavychain segments as the largely expanded clones ( fig. S5C) . Bars/lines indicate the median. Statistical significance from baseline or between groups was determined using Wilcoxon matched-pairs signed-rank test (**P < 0.005, ***P < 0.001, ****P < 0.0001). Significance between HA probes was determined using Wilcoxon matched-pairs signed-rank test (*P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001).
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A/Cal09-H1 + IgG + B cells (Fig. 2E) Vaccination substantially increased the number of B cells specific for three IIV components (P < 0.0001) (Fig. 3, A and B ). This increase was observed on d7, peaked at d14, and maintained until d28. Thus, IIV increases the size of the influenza-specific B cell pool, at least until d28 after immunization. For H3, HA-specific B cell patterns were similar when data were analyzed from both the 2015 cohort (using a homologous probe) and the 2016 cohort (using a heterologous probe) together ( from d7 until d28, with a noticeable peak on d14 (Fig. 3, F and G + influenza-specific B cells, peaking on d14. We further investigated how these cellular events are connected and how they relate to the magnitude of the serological response. Because the 2016 vaccine formulation included a new H3N2 strain and a second IBV strain, for which rHA + probes were unavailable, the analysis focused on the 2015 cohort (n = 16). For other analyses, pooled data from the 2015 and 2016 cohorts (n = 42) were used.
A correlation between the number of blood ASCs per microliter on d7 and the antibody response after IIV (total fold change on d28 over d0) (r s = 0.37, P = 0.013) was found (Fig. 4A ). The total fold increase was defined as the sum of the fold change for all the vaccine components, because the cT FH 1 and ASCs detected on d7 could not be attributed to a specific vaccine component. Accordingly, individuals who seroconverted after IIV (≥4-fold change in HAI titers to at least one vaccine component) had a significantly higher ASC/l numbers at d7, as compared to nonseroconverters (P = 0.0381) (Fig. 4B) , as in studies showing that the serological response to vaccination was linked to the emergence of ASCs (2, 24) . In the 2014 cohort with longitudinal serum samples, the HAI titer increased as early as d7 (Fig. 4C) , suggesting that the serological response observed after vaccination is derived from this transient ASC population.
Similarly, ICOS + PD-1 + cT FH 1 cells showed a moderate correlation with the total fold increase in HAI titers (r s = 0.43, P = 0.0042) (Fig. 4D) . Notably, seroconverters had a higher number of ICOS + PD-1 + cT FH 1 cells when compared to nonseroconverters (P = 0.0328) (Fig. 4E) . In addition, the number of ASCs on d7 showed a moderate positive correlation with the number of ICOS + PD-1 + cT FH 1 cells on d7 (r s = 0.6307, P < 0.0001) (Fig. 4F) . Furthermore, the number of ICOS + influenza-specific B cells Individuals who seroconverted to H1 and B had lower serum titers at baseline than those who did not respond to the vaccine (H1: P = 0.0062; B: P = 0.0045) (Fig. 5A) , showing that seroconversion is influenced by preexisting serum titers, as reported (17) . This was not observed for H3N2 (P = 0.29), which differed in both 2015 and 2016. Correspondingly, preexisting titers to H1 and B components showed a negative correlation with the cognate fold increase in HAI titers from baseline was determined using Wilcoxon matched-pairs signed-rank test (*P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001).
(H1: r s = −0.5, P = 0.001; B: r s = −0.55, P = 0.0001) (Fig. 5B) . This differed for the drifted H3 component (r s = −0.29, P = 0.06). When HAI titers against all vaccine components were added, there was a significantly strong negative correlation between the baseline HAI titers and the fold increase in HAI titers on d28/d0 (r s = −0.56, P = 0.0001) (Fig. 5C) . Conversely, the total preexisting serum titers on d0 did not affect the emergence of total ASCs (r s = 0.063, P = 0.69) (Fig. 5D) or ICOS + PD-1 + cT FH 1 cells (r s = −0.02571, P = 0.8716) (Fig. 5E ) at d7. In addition, preexisting serum titers had no effect on the fold change of memory CD21 hi rHA + B cells for either of the components (H1: r s = −0.16, P = 0.54; B: r s = −0.12, P = 0.67; H3: r s = 0.08, P = 0.76) (Fig. 5F ). However, preexisting titers against B, but not H1 or H3, negatively correlated with the fold change of cognate CD21 lo rHA + B cells (H1: r s = −0.35, P = 0.2; B: r s = −0.76, P = 0.0015; H3: r s = −0.0045, P = 0.992) (Fig. 5G) . Thus, preexisting serological memory can limit seroconversion and the magnitude of CD21 (Fig. 6, C and D) or differentiation status (CD27/CD45RA phenotype) (Fig. 6 , E and F) of tetramer + CD8 + T cells. Last, there were no differences in the expression of differentiation (CD27/ CD45RA), activation (HLA-DR/CD38), or proliferation (Ki-67) markers (Fig. 6G) or the effector granzyme B on T cells (n = 14) ( fig. S12) . Overall, influenza-specific T cell compartments in the circulation (with the exception of CD4 + T cells) remain unchanged after IIV.
Vaccine-induced memory B cells are not maintained in peripheral blood
For vaccine-induced immunity to be protective, it needs to be longlived. We assessed the longevity of vaccine-induced influenza-specific antibodies and B cells. Serum titers (but not influenza-specific B cells) for the three vaccine components were stable (within the fourfold difference) over the 1-year period (>350 days) after vaccination (Fig. 7,  A (Fig. 7, F and G) . However, when the fold change over its respective baseline for each year was calculated, B cell responses were significantly larger on d7 (P < 0.05) in the second year for total rHA + B cells and for IgG + CD21 hi rHA + B cells ( fig. S13 ). Although these findings are interesting, the small number of donors and the lack of a vaccination history precluded us from further dissecting the effects of previous vaccination on influenza-specific B cell responses.
B cells show distinct patterns of tissue compartmentalization
Because the loss of vaccine-induced B cell memory in blood could result from transition between phenotypes, contraction of vaccineinduced B cell pools, or migration of memory B cells into tissues, we analyzed the distribution and phenotype of total and influenzaspecific B cells across seven human tissue compartments. Spleens, lungs, and lymph nodes were obtained from deceased organ donors, whereas peripheral blood, bone marrow, cord blood, and tonsils were obtained from healthy individuals. B cells were phenotypically divided into four populations based on the expression of CD27 and CD21. Naïve B cells were defined as CD21 − B cells were enriched in secondary lymphoid organs (SLOs), with a median of ~50% lymphocytes being B cells in the tonsils, lymph nodes, and spleen, as compared to 6.5% in adult blood, 13.7% in cord blood, 11.1% in bone marrow, and 4.8% in the lung (Fig. 8A) . Naïve B cells (CD21 hi CD27 − ) were found in human tissues, alongside the other B cell subsets (Fig. 8B) . Most of the naïve B cells were detected in cord blood (86.4%) and bone marrow (88.3%), consistent with the lack of antigen exposure in cord blood and the development of B cells in the bone marrow. About 75% of blood and tonsil B cells were unswitched, whereas the spleen and lymph nodes contained a higher proportion of resting memory B cells (48.2 and 63.3%). The human lung contained 58% resting memory B cells and 38.6% unswitched B cells. Activated memory (CD21 lo CD27 + ) B cells were infrequent, consistent with the donors' healthy status. Similar results were obtained from isotype analysis across human tissues (Fig. 8C) . IgD (Fig. 8F) . Overall, influenza-specific B cell memory is enriched outside of peripheral blood.
To normalize for differences between donors due to exposure history and age, we analyzed B cell tissue compartmentalization in paired peripheral blood and spleen samples (n = 5; table S2). Analysis of total B cells confirmed enrichment of CD21 hi CD27
+ memory in the spleen compared to blood (Fig. 8H) and differential distribution of different isotypes between blood and tissues ( fig. S15) . Because of the low cell numbers available, we could not confidently detect influenzaspecific B cells.
DISCUSSION
Vaccination with inactivated influenza remains the predominant prophylactic measure against infection. Understanding the cellular events that precede the induction of protective immunity is pivotal in the development of better vaccines. We provide a comprehensive analysis of the immune response to vaccination in healthy individuals. Using rHA probes to characterize influenza-specific B cells, we show that vaccination induces an early wave of influenza-specific short-lived effectors (ASCs), accompanied by an increase in antibody titers, and a second wave of CD21 In addition, our serological analysis by HAI only measures antibodies that block the receptor binding site but not the broadly cross-reactive anti-HA stem antibodies and does not distinguish between isotypes. Nonetheless, our study provides insights into the human B cell response and recapitulates fundamental aspects of B cell biology from animals, translating them into humans across different tissues. Previously, ASCs on d7 correlated with seroconversion (2, 24). Our kinetic data and correlation analyses support this model. Consistent with studies in mice (25, 26) and tetanus vaccination in humans (27) , our findings show that the emergence of ASCs is accompanied by a chemotactic switch, specifically the loss of CXCR5, releasing B cells from germinal centers and preventing their reentry, and up-regulation of CXCR3, directing them to sites of inflammation and likely the bone marrow (28) . The CD21 hi CD27
+ population represents a resting B cell memory population. These memory cells were detected in blood at steady state and in tissues, with their numbers being transiently boosted by vaccination. Activated memory CD21 lo CD27
+ B cells are distinct from ASCs because they express CD20. These cells were detectable at steady state in blood and tissues but emerged after vaccination. The fate of each population remains unclear, with both CD21 hi and CD21 lo cells persisting for at least 4 weeks, but subsiding by 1 year after vaccination.
Recent reports described human antigen-specific B cells with low CD21 expression. A newly described B cell phenotype (CD38 (12, 13) . Seminal studies showed that specialization occurs between different cT FH subsets and their ability to stimulate naïve or memory B cells to differentiate into ASCs (12, 13) . In that regard, cT FH 1 cells have a prominent role in facilitating seroconversion after vaccination, which is predominantly memory-derived (2, 11) . However, on the basis of current data, the role of cT FH cells during IIV is limited to the interplay with serum antibodies. We show that activation of cT FH Preexisting serological memory affected the magnitude of the serological response, and individuals who did not seroconvert had higher HAI titers at baseline than seroconverters, consistent with previous observations (17, 30) . The mechanism is unclear, but others suggested that preexisting antibodies mask or block antigenic epitopes on HA and/or induce the formation of immune complexes, which could aid antigen clearance, thus limiting the B cell response (17, 31) . We found an effect of serum titers at baseline on the magnitude of CD21 cord blood, n = 5; bone marrow, n = 5; tonsil, n = 5; lymph node, n = 3; lung, n = 3; spleen, n = 7.
(H) PBMCs from paired blood and spleen samples were analyzed. Frequency of each CD21/ CD27 population within total B cells for each blood and spleen pair (n = 5) is shown. Significance was assessed using a paired t test (*P < 0.05; **P < 0.005). ND, not determined.
B cells on d14, although this was only observed for IBV. It is also possible, however, that seroconversion (fourfold change in titers) is harder to detect in individuals with preexisting high titers. Despite the substantial effects of IIV on the B cell and CD4 + /T FH compartments, other T cell populations were apparently unaffected. Specifically, IAV-and IBV-specific CD8 + T cells were unaffected in frequency and phenotype. Whether this is due to antigen content, inadequate inflammation, or lack of cross-presentation in the absence of viral replication is unclear. Given the prominent role of CD8 + T cells in cross-protective immunity (4-6), even against antigenically shifted strains like avian H5N1 (32) and H7N9 (6, 33) , vaccines that establish CD8 + T cells are of considerable importance. Although vaccination induced robust humoral immunity, the B cell response was not maintained in peripheral blood over time. This likely reflects the expected contraction of B cells and their migration to lymphoid tissues. Although we cannot infer the relative contribution of contraction and tissue compartmentalization in the observed loss of memory B cells from blood, nor do we know the vaccination and infection history of our donors, our data indicate that memory B cells are enriched in tissues compared to blood. Accordingly, vaccination in consecutive years induced earlier and larger B cell responses, despite disappearance of vaccine-induced memory from blood. Similarly, robust memory responses were detected after vaccination following B cell depletion by rituximab, implying the presence of memory reservoirs in tissues (34) . Our data agree with reports on compartmentalization of human virus-specific memory B cells in the spleen (35) and distribution of influenza-specific memory B cells across tissues in mice (36) . Our analysis supports the notion that the assessment of long-term vaccine effectiveness in blood may be suboptimal. Notably, our study suggests that vaccine design needs to consider the localization of memory B cells and the fact that vaccination route affects the B cell response to vaccination (37) .
Together, we show that activation of cT FH cells, serological memory, and tissue compartmentalization are key factors in human antigenspecific B cell responses. Our study has implications for the design of effective vaccines against influenza viruses and highlights avenues for further research. Specifically, determining ways to activate cT FH cells and CD8 + T cells is of utmost importance. It would be pertinent to understand whether and how the limiting effects of preexisting antibodies on the B cell response can be overcome. Differential compartmentalization of influenza-specific B cell subsets across human tissues and the prominent presence of memory B cells in the lung should be considered with regard to the vaccination route because intranasal vaccination might be more effective in stimulating the influenza-specific memory pool. Further understanding the fate of each B cell population after vaccination will be fundamental to establishing long-lasting serological and cellular immune memory to influenza viruses.
MATERIALS AND METHODS
Study design
This study aimed to dissect the influenza-specific B and T cell responses after vaccination with split inactivated influenza viruses and across human tissues. To that end, 35 healthy adults (>18 years old) were vaccinated over 3 years (2014 to 2016) with the trivalent influenza vaccine (2014, n = 7; 2015, n = 16) or the 2016 quadrivalent influenza vaccine (2016, n = 26), with selected individuals participating in consecutive years (table S1) . Peripheral blood samples were collected in heparinized tubes before vaccination (d−1 or d0) and on d7, d14, and d28 after vaccination. For individuals participating in both 2015 and 2016 years, the 2016 baseline sample was used as the 1-year time point (>350 days). Influenzaspecific B cells were identified using rHA probes and flow cytometry. ASCs and serum antibody titers were assessed in all three cohorts. cT FH and influenza-specific B cells were assessed in the 2015 and 2016 cohorts. Cellular immunity was assessed in selected donors from the 2014 to 2015 cohort. One donor in the 2016 cohort reported feeling unwell with symptoms of unrelated sickness, and those samples were excluded from analysis. In cases where less than the total number of donors was analyzed, donors were randomly selected for analysis. No other blinding or randomization protocols were applied, and no outliers were excluded. Primary data are reported in table S9. Spleen, lung, and lymph node samples were obtained from deceased organ donors. Spleen and lymph node samples were obtained via DonateLife Victoria (table S2) . Lung samples were obtained via the Alfred Hospital's Lung Tissue Biobank. Tonsils were obtained from healthy individuals undergoing tonsillectomy (Mater Hospital). PBMCs were isolated from buffy packs obtained from the ARCBS. Umbilical cord blood was obtained via the Mercy Women's Hospital. Bone marrow mononuclear cells, isolated from the posterior ileac crests of healthy volunteers, were commercially purchased (Lonza).
Human blood and tissue samples
Statistical analysis
Significance was assessed using Wilcoxon matched-pairs signed-rank test (for changes from baseline) or Friedman test (for comparisons between multiple time points). Mann-Whitney test was used to compare unpaired samples, and a paired t test was used to compare paired tissue samples. Correlations were assessed using Spearman's correlation coefficient (r s ) for non-Gaussian distributions.
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